REFERENCES
ACCP Abstract Booklet. (2021). Clinical Pharmacology in Drug
Development, 10 (S1), 1-104. doi:https://doi.org/10.1002/cpdd.1004
Avedissian, S. N., Pais, G. M., Liu, J., Rhodes, N. J., & Scheetz, M.
H. (2019). Piperacillin-Tazobactam Added to Vancomycin Increases Risk
for AKI: Fact or Fiction? Clin Infect Dis doi:10.1093/cid/ciz1189
Avedissian, S. N., Pais, G. M., O’Donnell, J. N., Lodise, T. P., Liu,
J., Prozialeck, W. C., … Scheetz, M. H. (2019). Twenty-four hour
pharmacokinetic relationships for intravenous vancomycin and novel
urinary biomarkers of acute kidney injury in a rat model. J
Antimicrob Chemother, 74 (8), 2326-2334. doi:10.1093/jac/dkz167
Baggs, J., Fridkin, S. K., Pollack, L. A., Srinivasan, A., & Jernigan,
J. A. (2016). Estimating National Trends in Inpatient Antibiotic Use
Among US Hospitals From 2006 to 2012. JAMA Intern Med, 176 (11),
1639-1648. doi:10.1001/jamainternmed.2016.5651
Becerir, T., Tokgün, O., & Yuksel, S. (2021). The therapeutic effect of
Cilastatin on drug-induced nephrotoxicity: a new perspective. Eur
Rev Med Pharmacol Sci, 25 (17), 5436-5447.
doi:10.26355/eurrev_202109_26651
Chang, J., Pais, G. M., Valdez, K., Marianski, S., Barreto, E. F., &
Scheetz, M. H. (2022). Glomerular Function and Urinary Biomarker Changes
between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a
Translational Rat Model. Antimicrob Agents Chemother, 66 (3),
e0213221. doi:10.1128/aac.02132-21
Christensen, E. I., Nielsen, S., Moestrup, S. K., Borre, C., Maunsbach,
A. B., de Heer, E., … Verroust, P. (1995). Segmental distribution
of the endocytosis receptor gp330 in renal proximal tubules. Eur J
Cell Biol, 66 (4), 349-364.
Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C.
H., Giembycz, M. A., … Ahluwalia, A. (2018). Experimental design
and analysis and their reporting II: updated and simplified guidance for
authors and peer reviewers. Br J Pharmacol, 175 (7), 987-993.
doi:10.1111/bph.14153
Guidance for Industry. Estimating the Maximum Safe Starting Dose in
Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.
U.S. Department of Health and Human Services. Food and Drug
Administration. Center for Drug Evaluation and Research (CDER). .
(2005). In.
H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag
New York, 2016.
Hakeam, H. A., AlAnazi, L., Mansour, R., AlFudail, S., & AlMarzouq, F.
(2019). Does nephrotoxicity develop less frequently when vancomycin is
combined with imipenem-cilastatin than with meropenem? A comparative
study. Infect Dis (Lond), 51 (8), 578-584.
doi:10.1080/23744235.2019.1619934
He, M., Souza, E., Matvekas, A., Crass, R. L., & Pai, M. P. (2021).
Alteration in Acute Kidney Injury Potential with the Combination of
Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam
in a Preclinical Model. Antimicrob Agents Chemother,
65 (4)doi:10.1128/AAC.02141-20
Hori, Y., Aoki, N., Kuwahara, S., Hosojima, M., Kaseda, R., Goto, S.,
… Saito, A. (2017). Megalin Blockade with Cilastatin Suppresses
Drug-Induced Nephrotoxicity. J Am Soc Nephrol, 28 (6), 1783-1791.
doi:10.1681/ASN.2016060606
Humanes, B., Jado, J. C., Camano, S., Lopez-Parra, V., Torres, A. M.,
Alvarez-Sala, L. A., … Lazaro, A. (2015). Protective Effects of
Cilastatin against Vancomycin-Induced Nephrotoxicity. Biomed Res
Int, 2015 , 704382. doi:10.1155/2015/704382
Im, D. S., Shin, H. J., Yang, K. J., Jung, S. Y., Song, H. Y., Hwang, H.
S., & Gil, H. W. (2017). Cilastatin attenuates vancomycin-induced
nephrotoxicity via P-glycoprotein. Toxicol Lett, 277 , 9-17.
doi:10.1016/j.toxlet.2017.05.023
Kahan, F. M., Kropp, H., Sundelof, J. G., & Birnbaum, J. (1983).
Thienamycin: development of imipenen-cilastatin. J Antimicrob
Chemother, 12 Suppl D , 1-35. doi:10.1093/jac/12.suppl_d.1
Kusama, M., Yamamoto, K., Yamada, H., Kotaki, H., Sato, H., & Iga, T.
(1998). Effect of cilastatin on renal handling of vancomycin in rats.J Pharm Sci, 87 (9), 1173-1176. doi:10.1021/js9801135
Kuwahara, S., Hosojima, M., Kaneko, R., Aoki, H., Nakano, D., Sasagawa,
T., … Saito, A. (2016). Megalin-Mediated Tubuloglomerular
Alterations in High-Fat Diet-Induced Kidney Disease. J Am Soc
Nephrol, 27 (7), 1996-2008. doi:10.1681/ASN.2015020190
Legg, A., Meagher, N., Johnson, S. A., Roberts, M. A., Cass, A.,
Scheetz, M. H., … Tong, S. Y. C. (2022). Risk Factors for
Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus
Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial. Clin Drug
Investig doi:10.1007/s40261-022-01204-z
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K.,
Gorwitz, R. J., … Chambers, H. F. (2011). Clinical practice
guidelines by the infectious diseases society of america for the
treatment of methicillin-resistant Staphylococcus aureus infections in
adults and children. Clin Infect Dis, 52 (3), e18-55.
doi:10.1093/cid/ciq146
Liu, J., Tong, S. Y. C., Davis, J. S., Rhodes, N. J., Scheetz, M. H., &
Group, C. S. (2020). Vancomycin Exposure and Acute Kidney Injury
Outcome: A Snapshot From the CAMERA2 Study. Open Forum Infect Dis,
7 (12), ofaa538. doi:10.1093/ofid/ofaa538
Lodise, T. P., Rosenkranz, S. L., Finnemeyer, M., Evans, S., Sims, M.,
Zervos, M. J., … Holland, T. L. (2020). The Emperor’s New
Clothes: PRospective Observational Evaluation of the Association Between
Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd
Patients With Methicillin-resistant Staphylococcus aureus Bloodstream
Infections (PROVIDE). Clin Infect Dis, 70 (8), 1536-1545.
doi:10.1093/cid/ciz460
Moestrup, S. K., Cui, S., Vorum, H., Bregengård, C., Bjørn, S. E.,
Norris, K., … Christensen, E. I. (1995). Evidence that epithelial
glycoprotein 330/megalin mediates uptake of polybasic drugs. J
Clin Invest, 96 (3), 1404-1413. doi:10.1172/jci118176
Nakamura, T., Kokuryo, T., Hashimoto, Y., & Inui, K. I. (1999). Effects
of fosfomycin and imipenem-cilastatin on the nephrotoxicity of
vancomycin and cisplatin in rats. J Pharm Pharmacol, 51 (2),
227-232. doi:10.1211/0022357991772187
National Research Council (US) Committee for the Update of the Guide for
the Care and Use of Laboratory Animals. Guide for the Care and Use of
Laboratory Animals. 8th edition. Washington (DC): National Academies
Press (US); 2011. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK54050/ doi: 10.17226/12910.
In.
Pais, G. M., Avedissian, S. N., O’Donnell, J. N., Rhodes, N. J., Lodise,
T. P., Prozialeck, W. C., … Scheetz, M. H. (2019). Comparative
Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury
According to Timeline of Injury. Antimicrob Agents Chemother,
63 (7), e00079-00019. doi:10.1128/AAC.00079-19
Pais, G. M., Chang, J., Liu, J., & Scheetz, M. H. (2022). A
translational rat model to assess glomerular function changes with
vancomycin. Int J Antimicrob Agents, 59 (5), 106583.
doi:10.1016/j.ijantimicag.2022.106583
Pais, G. M., Liu, J., Avedissian, S. N., Hiner, D., Xanthos, T.,
Chalkias, A., … Scheetz, M. H. (2020). Lack of synergistic
nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat
model and a confirmatory cellular model. J Antimicrob Chemother,
75 (5), 1228-1236. doi:10.1093/jac/dkz563
Pais, G. M., Liu, J., Zepcan, S., Avedissian, S. N., Rhodes, N. J.,
Downes, K. J., … Scheetz, M. H. (2020). Vancomycin-Induced Kidney
Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human
Translation, and Potential Strategies for Prevention.Pharmacotherapy, 40 (5), 438-454. doi:10.1002/phar.2388
Primaxin Package insert.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf.
Merck 12/2016. In.
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu,
C., … Lomaestro, B. M. (2020). Therapeutic monitoring of
vancomycin for serious methicillin-resistant Staphylococcus aureus
infections: A revised consensus guideline and review by the American
Society of Health-System Pharmacists, the Infectious Diseases Society of
America, the Pediatric Infectious Diseases Society, and the Society of
Infectious Diseases Pharmacists. Am J Health Syst Pharm, 77 (11),
835-864. doi:10.1093/ajhp/zxaa036
Scheetz, M. H., Pais, G. M., Lodise, T. P., Tong, S. Y. C., Davis, J.
S., O’Donnell, J. N., … Avedissian, S. N. (2021). Of Rats and
Men: a Translational Model To Understand Vancomycin
Pharmacokinetic/Toxicodynamic Relationships. Antimicrob Agents
Chemother, 65 (10), e0106021. doi:10.1128/aac.01060-21
Suzuki, T., Yamaguchi, H., Ogura, J., Kobayashi, M., Yamada, T., &
Iseki, K. (2013). Megalin contributes to kidney accumulation and
nephrotoxicity of colistin. Antimicrob Agents Chemother, 57 (12),
6319-6324. doi:10.1128/aac.00254-13
Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson,
J., … Davis, J. S. (2020). Effect of Vancomycin or Daptomycin
With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia,
Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A
Randomized Clinical Trial. Jama, 323 (6), 527-537.
doi:10.1001/jama.2020.0103
Toyoguchi, T., Takahashi, S., Hosoya, J., Nakagawa, Y., & Watanabe, H.
(1997). Nephrotoxicity of vancomycin and drug interaction study with
cilastatin in rabbits. Antimicrob Agents Chemother, 41 (9),
1985-1990. doi:10.1128/AAC.41.9.1985
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013). Systematic
review and meta-analysis of vancomycin-induced nephrotoxicity associated
with dosing schedules that maintain troughs between 15 and 20 milligrams
per liter. Antimicrob Agents Chemother, 57 (2), 734-744.
doi:10.1128/AAC.01568-12
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel,
M. J., Baruch, A., … Chastre, J. (2012). Linezolid in
methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a
randomized, controlled study. Clin Infect Dis, 54 (5), 621-629.
doi:10.1093/cid/cir895